Cymbalta's Expanded GAD Claim Is A Load Off Lilly's Mind
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval for maintenance treatment of generalized anxiety disorder may be more about shoring up the blockbuster drug than creating a market for growth.
You may also be interested in...
Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication
Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.